Skye Bioscience Inc (SKYE)

$0.98 +0.04 (4.13%)
Market Cap 30.17M
Revenue (ttm) 0.00
Net Income (ttm) -26.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 197,000
Avg Vol 417,732
Day's Range N/A - N/A
Shares Out 32.06M
Stochastic %K 63%
Beta 2.68
Analysts Strong Sell
Price Target $8.71

Company Profile

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in Jan...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 410 0266
Address:
11250 El Camino Real, Suite 100, San Diego, United States
Jangalang
Jangalang Jan. 13 at 12:16 AM
$SKYE … Scam Bio Science.
0 · Reply
Jangalang
Jangalang Jan. 12 at 11:47 PM
$SKYE … Everyone on here should consider this investment a total loss. The actual company is spamming the message feed because that’s how desperate they are. SCAMMERS.
0 · Reply
Jangalang
Jangalang Jan. 12 at 11:46 PM
$SKYE … I am a complete moron for not selling this when I was in profit after they went live on NASDAQ. I am now down $15,000 on this scam stock. SCAMMERS.
0 · Reply
SkyeBioscience
SkyeBioscience Jan. 12 at 2:03 PM
As we look ahead, $SKYE continues to emphasize disciplined, focused execution across our clinical and development programs. Building on the Phase 2a CBeyond data generated in 2025, this year represents an important opportunity to advance our pipeline. Our priorities include delivering additional clinical readouts, evaluating higher doses of nimacimab, and preparing for a Phase 2b study assessing nimacimab in combination with an incretin therapy, while remaining focused on driving meaningful progress for patients and stakeholders.
1 · Reply
cat64
cat64 Jan. 11 at 8:30 PM
$SKYE The limitations of GLP 1 medicines. There is definitely a need for further treatment options and hopefully Nimacimab can fill that gap. https://theconversation.com/stopping-weight-loss-jabs-leads-to-much-faster-rebound-than-thought-so-are-they-still-worth-it-272314?utm_medium=article_clipboard_share&utm_source=theconversation.com
0 · Reply
Fellforit
Fellforit Jan. 9 at 9:02 PM
$SKYE oops..under 100 cents again
0 · Reply
SkyeBioscience
SkyeBioscience Jan. 8 at 10:20 PM
Skye has partnered with Halozyme Therapeutics to co-formulate nimacimab with its proprietary ENHANZE® technology, which enables higher-volume subcutaneous administration by temporarily modifying the extracellular matrix in the skin. This approach is designed to support faster injections, improved absorption, reduced injection-site discomfort, and enhanced bioavailability. We believe that co-formulating nimacimab with ENHANZE® will allow us to deliver the doses and volumes needed to achieve meaningful weight loss outcomes, while maintaining a subcutaneous injection experience comparable to currently available GLP-1 therapies. Watch our insight video here: https://skyebioscience.com/working-with-halozyme-enhanze-technology-for-higher-dosing/ $SKYE
2 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Jan. 8 at 9:45 PM
$SLS $SKYT $SKYE $RDW Results.
0 · Reply
YazzJr
YazzJr Jan. 8 at 2:53 PM
$SKYE I am thinking we see a run-up to the Feb 300mg results and hopefully with results that suggest that upping the dosage WILL work for weight loss, we should see a pop on that. I have a feeling there is a Big Pharma watching and if the 300mg dose does show that upping the dose will work, that SKYE either gets acquired or at least partnered up. But these 300mg dose results are super important. It will either allow SKYE to continue as a company if the results are solid or they will have to think about pivoting or closing up. But it really is do or die with these 300mg dose results. Fingers crossed.
2 · Reply
StockScanners
StockScanners Jan. 8 at 7:23 AM
$SKYE reached 1.17
1 · Reply
Latest News on SKYE
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Jan 12, 2026, 6:11 PM EST - 1 day ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Skye Provides 2026 Corporate Outlook

Jan 12, 2026, 7:00 AM EST - 1 day ago

Skye Provides 2026 Corporate Outlook

SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Jan 9, 2026, 9:45 AM EST - 4 days ago

SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Jan 7, 2026, 11:33 AM EST - 6 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Jan 6, 2026, 10:55 AM EST - 7 days ago

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

Jan 5, 2026, 7:00 AM EST - 8 days ago

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

HALO

Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE.

Dec 19, 2025, 2:56 PM EST - 25 days ago

Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE.

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation

Dec 8, 2025, 7:11 AM EST - 5 weeks ago

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation

Skye Bioscience to Participate in Upcoming Investment Conferences

Nov 24, 2025, 7:00 AM EST - 7 weeks ago

Skye Bioscience to Participate in Upcoming Investment Conferences

Skye Bioscience, Inc. (SKYE) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 10:41 PM EST - 2 months ago

Skye Bioscience, Inc. (SKYE) Q3 2025 Earnings Call Transcript

Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

Nov 10, 2025, 4:01 PM EST - 2 months ago

Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

Nov 5, 2025, 7:05 AM EST - 2 months ago

Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

Nov 5, 2025, 7:00 AM EST - 2 months ago

Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

Oct 28, 2025, 8:00 AM EDT - 2 months ago

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

CNTX

Skye Bioscience, Inc. - Special Call

Oct 6, 2025, 2:25 PM EDT - 3 months ago

Skye Bioscience, Inc. - Special Call

Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge

Oct 6, 2025, 1:09 PM EDT - 3 months ago

Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss

Oct 6, 2025, 10:39 AM EDT - 3 months ago

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss

Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

Oct 6, 2025, 7:09 AM EDT - 3 months ago

Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Oct 6, 2025, 7:00 AM EDT - 3 months ago

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Skye Bioscience: Promising Nimacimab Data Supports Buy Rating

Oct 1, 2025, 10:45 AM EDT - 3 months ago

Skye Bioscience: Promising Nimacimab Data Supports Buy Rating

Could This New Drug Be The Safer Way To Fight Obesity?

Sep 19, 2025, 2:19 PM EDT - 4 months ago

Could This New Drug Be The Safer Way To Fight Obesity?

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Sep 19, 2025, 7:00 AM EDT - 4 months ago

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 9:45 AM EDT - 4 months ago

Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

Sep 5, 2025, 1:35 PM EDT - 4 months ago

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

Skye Bioscience, Inc. (SKYE) Virtual KOL Event Transcript

Sep 5, 2025, 1:30 AM EDT - 4 months ago

Skye Bioscience, Inc. (SKYE) Virtual KOL Event Transcript

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Sep 4, 2025, 7:00 AM EDT - 4 months ago

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Sep 2, 2025, 7:00 AM EDT - 4 months ago

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Aug 27, 2025, 7:00 AM EDT - 4 months ago

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Aug 21, 2025, 7:00 AM EDT - 5 months ago

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 8:36 PM EDT - 5 months ago

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Aug 7, 2025, 4:01 PM EDT - 5 months ago

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Jul 30, 2025, 7:00 AM EDT - 5 months ago

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing

Jul 7, 2025, 11:59 PM EDT - 6 months ago

Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Jun 23, 2025, 7:00 AM EDT - 7 months ago

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Jangalang
Jangalang Jan. 13 at 12:16 AM
$SKYE … Scam Bio Science.
0 · Reply
Jangalang
Jangalang Jan. 12 at 11:47 PM
$SKYE … Everyone on here should consider this investment a total loss. The actual company is spamming the message feed because that’s how desperate they are. SCAMMERS.
0 · Reply
Jangalang
Jangalang Jan. 12 at 11:46 PM
$SKYE … I am a complete moron for not selling this when I was in profit after they went live on NASDAQ. I am now down $15,000 on this scam stock. SCAMMERS.
0 · Reply
SkyeBioscience
SkyeBioscience Jan. 12 at 2:03 PM
As we look ahead, $SKYE continues to emphasize disciplined, focused execution across our clinical and development programs. Building on the Phase 2a CBeyond data generated in 2025, this year represents an important opportunity to advance our pipeline. Our priorities include delivering additional clinical readouts, evaluating higher doses of nimacimab, and preparing for a Phase 2b study assessing nimacimab in combination with an incretin therapy, while remaining focused on driving meaningful progress for patients and stakeholders.
1 · Reply
cat64
cat64 Jan. 11 at 8:30 PM
$SKYE The limitations of GLP 1 medicines. There is definitely a need for further treatment options and hopefully Nimacimab can fill that gap. https://theconversation.com/stopping-weight-loss-jabs-leads-to-much-faster-rebound-than-thought-so-are-they-still-worth-it-272314?utm_medium=article_clipboard_share&utm_source=theconversation.com
0 · Reply
Fellforit
Fellforit Jan. 9 at 9:02 PM
$SKYE oops..under 100 cents again
0 · Reply
SkyeBioscience
SkyeBioscience Jan. 8 at 10:20 PM
Skye has partnered with Halozyme Therapeutics to co-formulate nimacimab with its proprietary ENHANZE® technology, which enables higher-volume subcutaneous administration by temporarily modifying the extracellular matrix in the skin. This approach is designed to support faster injections, improved absorption, reduced injection-site discomfort, and enhanced bioavailability. We believe that co-formulating nimacimab with ENHANZE® will allow us to deliver the doses and volumes needed to achieve meaningful weight loss outcomes, while maintaining a subcutaneous injection experience comparable to currently available GLP-1 therapies. Watch our insight video here: https://skyebioscience.com/working-with-halozyme-enhanze-technology-for-higher-dosing/ $SKYE
2 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Jan. 8 at 9:45 PM
$SLS $SKYT $SKYE $RDW Results.
0 · Reply
YazzJr
YazzJr Jan. 8 at 2:53 PM
$SKYE I am thinking we see a run-up to the Feb 300mg results and hopefully with results that suggest that upping the dosage WILL work for weight loss, we should see a pop on that. I have a feeling there is a Big Pharma watching and if the 300mg dose does show that upping the dose will work, that SKYE either gets acquired or at least partnered up. But these 300mg dose results are super important. It will either allow SKYE to continue as a company if the results are solid or they will have to think about pivoting or closing up. But it really is do or die with these 300mg dose results. Fingers crossed.
2 · Reply
StockScanners
StockScanners Jan. 8 at 7:23 AM
$SKYE reached 1.17
1 · Reply
BenKaitz
BenKaitz Jan. 7 at 8:14 PM
$SKYE started an initial on Monday afternoon. Up 25% so far.
0 · Reply
jackedmund99
jackedmund99 Jan. 7 at 4:30 PM
$SKYE his value is stock. It’s been attacked by the shorts and the lawyers. We’re all news about BC drugs out there and this company’s ability to interact with the existing ones and make it better. This company is gonna get bought out. That’s my opinion. I had a buck quarter stock right now dollar 15 it’s a cheap option that has no time limit. What the hell everybody can buy 5000 shares
0 · Reply
MissionaryTrader
MissionaryTrader Jan. 7 at 3:08 PM
$SKYE Analyst of H.C. Wainwright maintained a Buy rating on Skye Bioscience, retaining the price target of $20.00. https://www.tipranks.com/news/ratings/skye-bioscience-enhanze-partnership-unlocks-nimacimab-dosing-de-risks-phase-2b-path-and-supports-buy-rating-ratings
2 · Reply
MissionaryTrader
MissionaryTrader Jan. 7 at 10:26 AM
$SKYE https://www.cnbc.com/2026/01/07/big-pharma-race-to-snap-up-biotech-assets-as-170-billion-patent-cliff-looms.html
1 · Reply
StockScanners
StockScanners Jan. 7 at 5:37 AM
$SKYE keep watch if this holds above 1.00
0 · Reply
SS115
SS115 Jan. 7 at 12:12 AM
$SKYE I remember alerting this stock when it went from 1.50 to 19 right after the RS. What in the world is going on here now? Sheesh.
0 · Reply
MissionaryTrader
MissionaryTrader Jan. 6 at 9:02 PM
$SKYE
2 · Reply
cbryant025
cbryant025 Jan. 6 at 8:04 PM
$LHSW fat stack shorties!!! $SKYE $ANGH $SKYQ
0 · Reply
cbryant025
cbryant025 Jan. 6 at 8:02 PM
$LHSW little scalpy $SKYE
0 · Reply
cbryant025
cbryant025 Jan. 6 at 5:45 PM
$LHSW booom!! $SKYE
0 · Reply
DarkSonar
DarkSonar Jan. 6 at 4:59 PM
$SKYE Hmmm…huge gap down, litigation, I am kinda scared to do my DD on this stock and peel through the layers. Interesting set up but is never a good thing to see odds getting so stacked up against a company for a position. 🔬
0 · Reply
jackedmund99
jackedmund99 Jan. 6 at 4:47 PM
$SKYE this real value here in the technologies is the company’s already proven that they combine it with the existing drugs out there they get better performance, but the law firms have been hitting the stock daily for the last two months- constantly —-first class vultures working for shorts
0 · Reply